Cancer Cells from Blood Could Help Tailor Breast Cancer Treatment

Blood Test May Reduce Over-Treatment of Early-Stage Breast Cancer

at a Glance:

*⁢ What: Researchers developed a “labyrinth chip” to detect circulating cancer cells in blood⁢ samples,potentially allowing for more personalized breast cancer⁣ treatment.
* Where: University of Michigan and University of Kansas Medical‍ Center.
* When: Research published in Science Advances (2023). The labyrinth chip was launched⁢ in 2017.
* Why it Matters: Currently, all women diagnosed with early-stage ⁣(DCIS) breast cancer receive treatment (surgery, radiation, hormone therapy) due ⁣to the inability to predict which ⁢cancers will become invasive. this test could identify patients who don’t need aggressive treatment, sparing them unnecessary side effects and improving quality of life.
* What’s Next: Further research and clinical trials are needed to validate the biomarkers identified and implement the test into standard clinical practice.

Key Facts:

* Approximately⁤ 2.3 million women are currently living with breast cancer.
* Around 25% of diagnoses are DCIS (ductal carcinoma in situ) – early-stage, non-invasive cancer.
* ⁢10-53% of untreated DCIS⁢ cases⁢ become invasive.
* 10% of patients treated with surgery ⁣alone experience cancer recurrence within 10 years.
* The “labyrinth chip” separates cancer cells from blood samples,enabling diagnostic testing even with very small quantities of‍ cells.
* The goal is to identify biomarkers that predict cancer progression and guide treatment decisions.

Data Summary: